Amphastar Pharmaceuticals
AMPH
Market cap $1,000M

21.21 USD

+0.26

1.24%

At close Aug 1, 4:00 PM EDT

After hours

21.21

+0.00

0.00%

1 day

1.24%

5 days

-5.19%

1 month

-9.13%

3 months

-11.18%

6 months

-36.48%

Year to date

-41.67%

1 year

-50.04%

5 years

2.27%

10 years

30.68%

About: Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Employees: 2,028

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,327 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

90% more call options, than puts

Call options by funds: $637K | Put options by funds: $336K

3.34% less ownership

Funds ownership: 73.14% [Q4 2024] → 69.8% (-3.34%) [Q1 2025]

8% less funds holding

Funds holding: 262 [Q4 2024] → 240 (-22) [Q1 2025]

15% less repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 94

26% less capital invested

Capital invested by funds: $1.31B [Q4 2024] → $964M (-$342M) [Q1 2025]

32% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 50

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$30

41%

upside

Avg. target

$33

53%

upside

High target

$35

65%

upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

JP Morgan Ekaterina Knyazkova	41%upside $30	Neutral Downgraded	12 May 2025
Wells Fargo Cerena Chen	65%upside $35	Overweight Maintained	8 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about AMPH published over the past 30 days

Zacks Investment Research

Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

Amphastar Pharmaceuticals: Shares Are Interesting, And Options Even More

Amphastar is undervalued (~71% upside), but lacks an economic moat and faces modest growth, so I favor a cautious gradual strategy. The business is defensive, with a diversified product mix and pipeline, but faces headwinds from competition, tariffs, and patent expirations. My base-case DCF-based fair value is $38.23; even in a pessimistic scenario, the stock seems at least fairly valued, limiting downside risk.

Amphastar Pharmaceuticals: Shares Are Interesting, And Options Even More

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7th, 2025

RANCHO CUCAMONGA, CA / ACCESS Newswire / July 29, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2025 ended June 30, 2025, after the market closes on Thursday, August 7, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7th, 2025

Zacks Investment Research

What Makes Amphastar (AMPH) a New Buy Stock

Amphastar (AMPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Amphastar (AMPH) a New Buy Stock

Zacks Investment Research

Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?

Zacks Investment Research

Here's Why Amphastar (AMPH) is Poised for a Turnaround After Losing 13.1% in 4 Weeks

Amphastar (AMPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why Amphastar (AMPH) is Poised for a Turnaround After Losing 13.1% in 4 Weeks

Amphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga Headquarters

RANCHO CUCAMONGA, CA / ACCESS Newswire / July 14, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), a bio-pharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, has announced a multi-year expansion of its U.S. manufacturing operations at its headquarters in Rancho Cucamonga, California. The company plans to quadruple its production capacity at this location over the next three to five years, reinforcing its commitment to domestic pharmaceutical manufacturing and strengthening supply chain resilience.

Amphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga Headquarters

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 22, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5th, 2025, at 2:00 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Amphastar Pharmaceuticals: Navigating Through An Inflection Year

Amphastar Pharmaceuticals posted Q1 results last week that beat the bottom-line consensus. The stock appears cheap at under eight times forward earnings, but the company is going through an 'inflection year' with flat revenue growth and declining profits. Growth should return in 2026 thanks to upcoming product launches. Is the stock cheap enough to buy the recent dip in the shares?

Amphastar Pharmaceuticals: Navigating Through An Inflection Year

Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 9, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 2025 Bank of America Health Care Conference on Wednesday, May 14th, 2025, at 1:40 pm PT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference

See News Rankings

Charts implemented using Lightweight Charts™